1. A pharmaceutical depot preparation containing (I) 5-fluoro-2 - [[(1S) -1- (5-fluoro-2-pyridyl) ethyl] amino] -6 - [(5-isopropoxy-1H-pyrazole -3-yl) amino] pyridin-3-carbonitrile or a pharmaceutically acceptable salt thereof as a pharmaceutical agent (PA) and (II) a polymer that breaks down to create an acidic microclimate in which RA is released from the polymer upon polymer degradation. 2. The pharmaceutical depot preparation according to claim 1, wherein the polymer is selected from a polyester of hydroxy fatty acid and its derivatives, a polymer of alkyl α-cyanoacrylate, polyalkylene oxalate, polyorthoester, polycarbonate, polyorthocarbonate, polyamino acid, hyaluronic acid ester and mixtures thereof. The pharmaceutical depot preparation according to claim 2, wherein the polymer is a copolymer of lactic and glycolic acids. The pharmaceutical depot preparation according to claim 3, wherein the lactic and glycolic acid copolymer has a molar ratio: lactic acid: glycolic acid ranging from 100: 0 to 50: 50.5. The pharmaceutical depot preparation according to claim 4, wherein the lactic and glycolic acid copolymer has a molar ratio: lactic acid: glycolic acid 95: 5.6. The pharmaceutical depot preparation according to claim 4, wherein the lactic and glycolic acid copolymer has a molar ratio: lactic acid: glycolic acid 50: 50.7. The pharmaceutical depot preparation according to claim 1, which is prepared in the form of a preparation for the controlled and / or prolonged release of RA over a period of from about 10 to 90 days. The pharmaceutical depot preparation according to claim 7, which is prepared in the form of a preparation for the controlled and / or prolonged release of RA over a period of about 14 days. Pharmaceutical Depot1. Фармацевтический депо-препарат, содержащий (I) 5-фтор-2-[[(1S)-1-(5-фтор-2-пиридил)этил]амино]-6-[(5-изопропокси-1Н-пиразол-3-ил)амино]пиридин-3-карбонитрил или его фармацевтически приемлемую соль в качестве фармацевтического агента (РА)
